Compare FTAI Aviation Ltd (FTAI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Novo Nordisk A/S — how do they compare? FTAI Aviation Ltd trades at $199.72 (market cap $21.93B), while Novo Nordisk A/S trades at $51.58 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 10.1× FTAI Aviation Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| FTAI | NVO | |
|---|---|---|
Market Cap | $21.93B | $222.24B |
Sector | Industrials | Health |
52-Week High | $310.04 | $71.70 |
52-Week Low | $109.92 | $35.29 |
Enterprise Value | $24.97B | $241.20B |
Dividend Yield | 0.7% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
